Cyclophosphamide/Prednisone/ThalidomideLack of efficacy following off-label use

被引：0

|

作者：

机构：

来源：

Reactions Weekly | 2024年 / 2016卷 / 1期

关键词：

D O I：

10.1007/s40278-024-62649-0

中图分类号：

学科分类号：

摘要：

引用

收藏

页码：156 / 156

相关论文

共 50 条

[41] IbrutinibLack of efficacy following off-label use: case report
Reactions Weekly, 2025, 2042 (1) : 209 - 209
[42] InterferonLack of efficacy following off-label use: case report
Reactions Weekly, 2024, 2025 (1) : 231 - 231
[43] TocilizumabLack of efficacy following off-label use: case report
Reactions Weekly, 2022, 1887 (1) : 643 - 643
[44] DexamethasoneLack of efficacy following off-label use: case report
Reactions Weekly, 2022, 1936 (1) : 195 - 195
[45] ApixabanLack of efficacy following off-label use: case report
Reactions Weekly, 2022, 1935 (1) : 89 - 89
[46] Dexamethasone/remdesivir/tocilizumabLack of efficacy following off-label use
Reactions Weekly, 2024, 1999 (1) : 147 - 147
[47] OxcarbazepineLack of efficacy following off-label use: case report
Reactions Weekly, 2022, 1905 (1) : 409 - 409
[48] CabazitaxelLack of efficacy following off-label use: case report
Reactions Weekly, 2023, 1980 (1) : 102 - 102
[49] Multiple drugsLack of efficacy, and pneumonitis following off-label use
Reactions Weekly, 2024, 2017 (1) : 345 - 345
[50] Bevacizumab/steroids/thalidomideLack of efficacy and off label use: case report
Reactions Weekly, 2022, 1933 (1) : 120 - 120

← 1 2 3 4 5 →